Published online before print December 24, 2007, doi: 10.1161/CIRCULATIONAHA.107.741181
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;117:379-387.)
© 2008 American Heart Association, Inc.
Imaging |
Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis
From the Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston (M.N., R.W.); Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown (M.N., H.Z., S.H., P.P., D.E.S., E.A., F.K.S., R.W.); Donald W. Reynolds Cardiovascular Clinical Research Center on Atherosclerosis at Harvard Medical School, Boston, Mass (M.N., E.A., P.L., R.W.); Department of Cardiology, Massachusetts General Hospital, Boston (D.E.S.); and Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Mass (P.L.).
Correspondence to Ralph Weissleder, MD, PhD, MGH-CSB, 185 Cambridge St, Boston, MA 02114. E-mail rweissleder{at}mgh.harvard.edu
Received August 3, 2007; accepted October 19, 2007.
Background— Macrophages participate centrally in atherosclerosis, and macrophage markers (eg, CD68, MAC-3) correlate well with lesion severity and therapeutic modulation. On the basis of the avidity of lesional macrophages for polysaccharide-containing supramolecular structures such as nanoparticles, we have developed a new positron emission tomography (PET) agent with optimized pharmacokinetics to allow in vivo imaging at tracer concentrations.
Methods and Results— A dextranated and DTPA-modified magnetofluorescent 20-nm nanoparticle was labeled with the PET tracer 64Cu (1 mCi/0.1 mg nanoparticles) to yield a PET, magnetic resonance, and optically detectable imaging agent. Peak PET activity 24 hours after intravenous injection into mice deficient in apolipoprotein E with experimental atherosclerosis mapped to areas of high plaque load identified by computed tomography such as the aortic root and arch and correlated with magnetic resonance and optical imaging. Accumulated dose in apolipoprotein E–deficient aortas determined by gamma counting was 260% and in carotids 392% of respective wild-type organs (P<0.05 both). Autoradiography of aortas demonstrated uptake of the agent into macrophage-rich atheromata identified by Oil Red O staining of lipid deposits. The novel nanoagent accumulated predominantly in macrophages as determined by fluorescence microscopy and flow cytometry of cells dissociated from aortas.
Conclusions— This report establishes the capability of a novel trimodality nanoparticle to directly detect macrophages in atherosclerotic plaques. Advantages include improved sensitivity; direct correlation of PET signal with an established biomarker (CD68); ability to readily quantify the PET signal, perform whole-body vascular surveys, and spatially localize and follow the trireporter by microscopy; and clinical translatability of the agent given similarities to magnetic resonance imaging probes in clinical trials.
CLINICAL PERSPECTIVE
Related Article:
-
Clinical Summaries
Circulation 2008 117: 331-332.[Extract] [Full Text]
This article has been cited by other articles:
 |
|
 |
|
  D. P. Cormode, T. Skajaa, Z. A. Fayad, and W. J.M. Mulder Nanotechnology in Medical Imaging: Probe Design and Applications Arterioscler. Thromb. Vasc. Biol., July 1, 2009; 29(7): 992 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H.F. Rudd, F. Hyafil, and Z. A. Fayad Inflammation Imaging in Atherosclerosis Arterioscler. Thromb. Vasc. Biol., July 1, 2009; 29(7): 1009 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Jaffer, P. Libby, and R. Weissleder Optical and Multimodality Molecular Imaging: Insights Into Atherosclerosis Arterioscler. Thromb. Vasc. Biol., July 1, 2009; 29(7): 1017 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Bengel, T. Higuchi, M. S. Javadi, and R. Lautamaki Cardiac positron emission tomography. J. Am. Coll. Cardiol., June 30, 2009; 54(1): 1 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Hyafil, J.-C. Cornily, J. H.F. Rudd, J. Machac, L. J. Feldman, and Z. A. Fayad Quantification of Inflammation Within Rabbit Atherosclerotic Plaques Using the Macrophage-Specific CT Contrast Agent N1177: A Comparison with 18F-FDG PET/CT and Histology J. Nucl. Med., June 1, 2009; 50(6): 959 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sanz, P. R. Moreno, and V. Fuster The year in atherothrombosis. J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1326 - 1337. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Christen, M. Nahrendorf, M. Wildgruber, F. K. Swirski, E. Aikawa, P. Waterman, K. Shimizu, R. Weissleder, and P. Libby Molecular Imaging of Innate Immune Cell Function in Transplant Rejection Circulation, April 14, 2009; 119(14): 1925 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Adiguzel, P. J Ahmad, C. Franco, and M. P Bendeck Collagens in the progression and complications of atherosclerosis Vascular Medicine, February 1, 2009; 14(1): 73 - 89. [Abstract] [PDF]
|
|
|
|
 |
|
 E. A. Osborn and F. A. Jaffer The year in molecular imaging. J. Am. Coll. Cardiol. Img., January 1, 2009; 2(1): 97 - 113. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nahrendorf, D. E. Sosnovik, B. A. French, F. K. Swirski, F. Bengel, M. M. Sadeghi, J. R. Lindner, J. C. Wu, D. L. Kraitchman, Z. A. Fayad, et al. Multimodality Cardiovascular Molecular Imaging, Part II Circ Cardiovasc Imaging, January 1, 2009; 2(1): 56 - 70. [Full Text] [PDF]
|
|
|
|
|
|
L. Yvan-Charvet, C. Welch, T. A. Pagler, M. Ranalletta, M. Lamkanfi, S. Han, M. Ishibashi, R. Li, N. Wang, and A. R. Tall Increased Inflammatory Gene Expression in ABC Transporter-Deficient Macrophages: Free Cholesterol Accumulation, Increased Signaling via Toll-Like Receptors, and Neutrophil Infiltration of Atherosclerotic Lesions Circulation, October 28, 2008; 118(18): 1837 - 1847. [Abstract] [Full Text] [PDF]
|
|